The Pilot Study of Foscarnet Cream in the Treatment of Mucocutaneous Herpes Simplex Virus Infections in Immunocompromised Patients Unresponsive to Acyclovir Treatment

Inclusion Criteria Concurrent Medication: Allowed: Ganciclovir (provided drug was administered for at least 14 days prior to study entry, and the HSV isolate exhibits resistance against acyclovir). Other medication considered necessary for patient's welfare, at the discretion of the investigator. Patients must have: HIV infection or AIDS. Mucocutaneous HSV infection with at least one clinically evaluable lesion. Prior acyclovir without clinical benefit. Life expectancy of at least 3 months. Consent of parent or guardian if less than 18 years of age. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Known hypersensitivity to the study drug. Any medical, psychiatric, or other condition that would preclude study compliance. Incapable of self administration of medication or presence of a care provider administering medication. Concurrent Medication: Excluded: Intravenous foscarnet for current episode of HSV. Acyclovir, interferon, or any investigational drug that might have anti-HSV activity (e.g., 256U87, HPMPC, BVDaraU, trifluridine). Patients with the following prior condition are excluded: Previous participation in the study. Prior Medication: Excluded: Intravenous foscarnet within 2 months prior to study entry.